Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
h15H3-mcMMAF
- Development stage
- Preclinical
- Lead developer
- Skagen
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
h15H3-mcMMAF is an antibody-drug conjugate (ADC) developed by Seattle Genetics (now Seagen/Pfizer) that targets integrin alpha-V beta-6 (ITGAV-ITGB6). The ADC consists of a humanized monoclonal antibody (h15H3) conjugated to the microtubule-disrupting agent monomethyl auristatin F (MMAF) via a non-cleavable maleimidocaproyl (mc) linker. Integrin alpha-V beta-6 is an epithelial-specific receptor that is frequently overexpressed in various solid tumors, including cancers of the head and neck, pancreas, bladder, lung, ovary, and breast, while showing minimal expression in normal tissues. Upon binding to the target antigen, the ADC is internalized and undergoes lysosomal degradation, which releases the MMAF payload. MMAF then inhibits tubulin polymerization, leading to G2/M phase cell cycle arrest and apoptosis of the tumor cells.
- Other names
- h15H3-MMAFh-15H3-MMAFh 15H3-MMAF
02
Targets
αVβ6 (Integrin αVβ6)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on h15H3-mcMMAF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on h15H3-mcMMAF.